Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd is a commercial-stage biopharmaceutical company that develops and sells therapeutic and diagnostic radiopharmaceuticals. The company operates through three business segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its primary therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is currently in a Phase 3 clinical trial for patients with advanced prostate cancer. Telix Pharmaceuticals Ltd is also developing TLX250, an rADC for advanced metastatic kidney cancer; TLX101, a systemic therapy for glioblastoma; TLX66, a product candidate for bone marrow conditioning in hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for prostate cancer treatment. Further pipeline candidates include TLX592, a prostate cancer therapy candidate using its proprietary RADmAb-engineered antibody technology; TLX252 for advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for glioblastoma and multiple myeloma; TLX300 for soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In diagnostics, the company is developing BiPASS, which is in a Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. The company operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. It has a strategic collaboration with University Hospital Essen. Telix Pharmaceuticals Ltd was founded in 2015 and is headquartered in North Melbourne, Australia.